---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-25-000062"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2025-07-17T23:59:59+00:00"
generated_at: "2026-05-18T05:58:23.509098+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Keros doses first patient in Phase 3 RENEW trial of elritercept; $10M milestone from Takeda

## Summary
- First patient dosed in Phase 3 RENEW trial of elritercept for adults with transfusion-dependent anemia with very low, low, or intermediate risk MDS.
- Milestone payment of $10 million triggered from Takeda under global license agreement.
- Keros received $200M upfront in Feb 2025; eligible for milestones exceeding $1.1B and tiered royalties.
- RENEW is global, randomized, double-blind, placebo-controlled; primary endpoint is reduction in red blood cell transfusions.

## SEC filing metadata
- accession: 0001664710-25-000062
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2025-07-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000062/0001664710-25-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000062/kros-20250717.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-25-000062
- JSON: https://secwatch.observer/filing/0001664710-25-000062.json
- Plain text: https://secwatch.observer/filing/0001664710-25-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.